Research Article

Yifei Weng*

Investigation of molecular regulation mechanism under the pathophysiology of subarachnoid hemorrhage

https://doi.org/10.1515/biol-2021-0138
received September 06, 2021; accepted November 10, 2021

Abstract: This study aimed to investigate the molecular mechanism under the pathophysiology of subarachnoid hemorrhage (SAH) and identify the potential biomarkers for predicting the risk of SAH. Differentially expressed mRNAs (DEGs), microRNAs, and IncRNAs were screened. Protein–protein interaction (PPI), drug–gene, and competing endogenous RNA (ceRNA) networks were constructed to determine candidate RNAs. The optimized RNAs signature was established using least absolute shrinkage and selection operator and recursive feature elimination algorithms. A total of 124 SAH-related DEGs were identified, and were enriched in inflammatory response, TNF signaling pathway, and others. PPI network revealed 118 hub genes such as TNF, MMP9, and TLR4. Drug–gene network revealed that chrysin targeted more genes, such as TNF and MMP9. JMJDIC-AS-hsa-miR-204-HDAC4/SIRT1 and LINCO1144-hsa-miR-128-ADRB2/TGFBR3 regulatory axes were found from ceRNA network. From these networks, 125 candidate RNAs were obtained. Of which, an optimal 38 RNAs signatures (2 IncRNAs, 1 miRNA, and 35 genes) were identified to construct a Support Vector Machine classifier. The predictive value of 38 biomarkers had an AUC of 0.990. Similar predictive performance was found in external validation dataset (AUC of 0.845). Our findings provided the potential for 38 RNAs to serve as biomarkers for predicting the risk of SAH. However, their application values should be further validated in clinical.

Keywords: subarachnoid hemorrhage, RNAs, support vector machine classifier, biomarkers

1 Introduction

Intracranial aneurysm (IA) is one of the common neurological diseases, and its incidence rate in the general population is approximately 5% [1]. IA is characterized by localized dilation or ballooning of a cerebral artery. Once an IA ruptures, a subarachnoid hemorrhage (SAH) typically develops [2,3]. SAH is a severe subtype of stroke, occurring in people about 50 years old [4]. Previous research revealed that environmental exposures and genetic predisposition play a role in the susceptibility of SAH, and the estimated heritability is about 40% [5]. Recently, despite considerable advances in therapy for IAs, SAH remains a highly challenging condition associated with a high socioeconomic burden [6,7]. SAH is a critical disease that has to be treated immediately. Therefore, an in-depth understanding of the molecular mechanism of SAH is necessary for the treatment of SAH. In addition, early screening and early active management and prevention of SAH help to reduce the mortality and disability rate of SAH patients. For these two purposes, this study was designed to investigate the molecular mechanism under the pathophysiology of SAH and to identify potential biomarkers that could predict the risk of SAH.

With the development of bioinformatics, gene expression profiling has been widely used to identify the biomarkers for the diagnosis and treatment of SAH [8]. Wang et al. found that six hub genes, BASP1, CEBPB, ECHDC2, GZMK, KLHL3, and SLC2A3, were determined as biomarkers to assess the progression and rupture of IAs [3]. It is known that long non-coding RNAs (lncRNAs) interact with mRNAs, and microRNAs (miRNAs) regulate many processes, such as transcription, translation, regulation of cell differentiation and cell cycle [9]. Interestingly, non-coding RNAs, comprising miRNAs and lncRNAs, play an important role in IAs and SAH [10]. Besides, lncRNAs detected from the biological fluids may be used as non-invasive biomarkers for the diagnosis and prognosis of IAs and SAH [11]. For instance, lncRNA MALAT1 expression
was independently associated with the poor overall survival for IAs, and the overexpression of MALAT1 predicted an higher risk of death in IA patients [12]. Circulating miRNAs (such as miR-16 and miR-25) may be novel biological markers that are useful in assessing the likelihood of IA occurrence [13]. Unfortunately, because of poor understanding of the mechanisms of SAH, current diagnosis and treatment of SAH can be inconsistent and/or ineffective [14,15]. Especially, the effects of core RNAs on the progression and prognosis of SAH patients have not been fully identified.

In the present research, we aimed to screen the SAH-related RNAs as biomarkers to provide new insights for the early screening, diagnosis, and treatment of SAH. For this aim, GSE36791 [16] and GSE73378 [15] datasets from the Gene Expression Omnibus (GEO) database were reanalyzed. A flowchart presenting the experimental design of this study is illustrated in Figure 1.

### 2 Materials and methods

#### 2.1 Data collection and preprocessing

The microarray datasets searched by terms of “subarachnoid hemorrhage” and “Homo sapiens” were acquired in the GEO database as of 2 January 2021. For the purpose of this research, the dataset screening criteria were as follows: (1) blood samples; (2) samples of SAH patients and controls; and (3) the total number of samples >50. There were two datasets meeting the screening criteria, GSE73378 [15] and GSE36791 [16] datasets. The GSE73378 dataset had a total of 226 samples, of which 210 blood samples including 103 SAH samples and 107 control samples were analyzed in this study. GSE36791 dataset had a total of 61 blood samples including 43 SAH samples and 18 control samples. The platform of these two datasets was GPL10558 Illumina HumanHT-12 V4.0 expression beadchip. The corresponding

![Figure 1: Flow diagram of the present study.](image-url)
platform annotation files were downloaded from Ensembl genome browser 96 database. Then, the probes in the two datasets were annotated to lncRNAs, miRNAs, and mRNAs based on the annotation files. Of the two datasets, all the analyses were performed based on GSE73378 dataset, and GSE36791 was used just for validation of the expression and predictive performance of the selected feature RNAs.

2.2 Assessment of differentially expressed RNAs

In GSE73378 dataset, the differentially expressed mRNAs (DEGs), miRNAs (DEMs), and lncRNAs (DEls) from SAH samples and normal samples were analyzed using the limma package (Version 3.34.7) [17] in R 3.6.1 language. The cutoff for differentially expressed RNAs (RNAs) screening was a false discovery rate (FDR) < 0.05 and \(|\log_2 FC| > 0.263\) (1.2 fold changes). Euclidean distance-based two-way hierarchical clustering analysis [18,19] was performed for the identified DERs using the heatmap package (Version 1.0.8) [20] in R 3.6.1 language.

2.3 SAH-related DEGs screening and functional enrichment analysis

SAH-associated genes were downloaded from DisGeNET database [21] by term of “subarachnoid hemorrhage.” The SAH-associated genes from DisGeNET database were used as the reference gene sets, gene set enrichment analysis was performed for all genes detected in GSE73378 dataset (genes were ranked by corresponding log FC value) using GSEA software (http://software.broadinstitute.org/gsea/index.jsp) [22] to further identify SAH-associated genes from GSE73378 dataset. Then, the obtained SAH disease-related genes were merged with DEGs, and the overlapped genes were selected as the SAH-related DEGs. The SAH-related DEGs were used to perform Gene Ontology (GO) enrichment analysis (biological process) and Kyoto Encyclopedia of Genes and Genomes (KEGG) analyses with the DAVID online tool (version 6.8) [23,24]. FDR < 0.05 was considered to be significantly enriched.

2.4 Construction of protein–protein interaction (PPI) network

Interactions among the protein-coding genes in SAH-related DEGs were retrieved from the STRING database (Version 11.0) [25] with PPI score of 0.4. PPI network was visualized using Cytoscape software (Version 3.6.1) [26] based on interaction pairs.

2.5 Construction of the drug–gene network

Connectivity Map (CMap) resource was created to connect human diseases with the genes that underlie them and drugs that treat them. CMap is the first installment of a reference collection of gene-expression profiles from cultured human cells treated with small bioactive molecules, for uncovering the functional connections among diseases, genetic perturbation, and drug action [27,28]. The Comparative Toxicogenomics Database (CTD) is a public resource based on published literature, manually curated associations among genes, chemicals, phenotypes, diseases, and environmental exposures [29]. To predict the small molecule drugs that target the SAH-related DEGs, both CMap and CTD were used. First, SAH-related DEGs were searched from CMap database to obtain the drug molecule–gene interactions. Second, the SAH-related DEGs were uploaded to CTD database to obtain the drug molecule–gene interactions. Then, the overlapped drug molecule–gene interactions from the two databases were selected. Finally, the drug–gene network was visualized based on the selected drug molecule–gene interactions using Cytoscape 3.6.1 software.

2.6 Construction of competing endogenous RNA (CeRNA) network

The connection relationship between DEls and DEMs was conducted by the DIANA-LncBase v2 database [30], and the lncRNA–miRNA interactions with negative correlations of their expression level were selected. The DEMs-associated target genes (miRNA–mRNA) were predicted using five miRNA databases including TargetScan Version 7.2 [31], picTar [32], miRanda [33], RNA22 [34], and PITA [35]. The miRNA–target gene interaction pairs were selected if they were predicted in more than three databases and were further filtered by SAH-related DEGs. Finally, the ceRNA network was established by integrating lncRNA–miRNA interactions and miRNA–mRNA interactions using Cytoscape 3.6.1 software.

2.7 Screening of optimal RNAs signature

All RNAs (mRNAs, miRNAs, and lncRNAs) contained in these three networks were used to screen characteristic RNAs by two different algorithms: least absolute shrinkage
and selection operator (LASSO) and recursive feature elimination (RFE). In brief, R 3.6.1 lars package (Version 1.2, https://cran.r-project.org/web/packages/lars/index.html) [36] was used to perform the regression analysis to screen characteristic RNAs. The RFE algorithm in the R 3.6.1 caret package (Version 6.0-76, https://cran.r-project.org/web/packages/caret/index.html) [37] was also used to screen the optimal characteristic RNAs. Then, we compared the results of the two algorithms and selected the overlapping RNAs as the final feature RNAs signature.

2.8 Evaluation and validation of optimal RNAs signature

We first extracted the expression of the optimal feature RNAs from GSE73378 dataset and GSE36791 dataset. Their expression levels in SAH and normal samples were displayed. Afterward, the Support Vector Machine (SVM) from R 3.6.1 e1071 (Version 1.6-8, https://cran.r-project.org/web/packages/e1071) [38] was used to construct the SVM classifier based on the optimal feature RNAs signature (Core: Sigmoid Kernel; Cross: 100-fold cross-validation). Both GSE73378 dataset and GSE36791 dataset were used for classifier construction. Receiver operating characteristic (ROC) curve analysis was performed with R 3.6.1 pROC (Version 1.12.1, https://cran.r-project.org/web/packages/pROC/index.html) [39] to calculate the performance of the SVM classifier for SAH. The R codes used in this study have been provided in an additional file.

3 Results

3.1 Differentially expressed RNAs in SAH

A total of 920 lncRNAs, 351 miRNAs, and 14,898 mRNAs were annotated. Then, 663 differentially expressed RNAs (including 17 DELs, 25 DEMs, and 621 DEGs) were identified based on the cutoff value of |log2 FC| > 0.263 and FDR < 0.05. Of which 228 RNAs were upregulated, and 435 were downregulated (Figure 2a). The heatmap showed samples could be obviously distinguished into SAH and normal groups based on the differential expression level of DERs (Figure 2b).

![Figure 2: Differentially expressed RNAs analysis. (a) Volcano plot of DERs identified using the edgeR package. Red and green points indicated upregulated and downregulated DERs, respectively (|log2 FC| > 0.263), FC: fold change. (b) Pheatmap of DERs. Black and white color indicated the samples from patients with SAH and controls, respectively.](image-url)
Figure 3: Identification of differentially expressed genes related with SAH. (a) Gene set enrichment analysis (GSEA) identified SAH-related genes. (b) The significantly enriched biological processes and (c) KEGG pathways.
3.2 SAH-related DEGs identification and function enrichment

From the DisGeNET database, a total of 470 genes associated with SAH were obtained. Then, GSEA was performed for all genes in SAH with the reference gene sets of SAH-associated genes from DisGeNET, and a total of 354 SAH-related genes were obtained (Figure 3a). Next the 354 SAH-related genes were compared with 621 DEGs, and a total of 124 overlapping genes were obtained as SAH-related DEGs. Enrichment analysis showed that these genes were enriched in 106 GO biological processes, such as GO:0071260 – cellular response to mechanical stimulus, GO:0045944 – positive regulation of transcription from RNA polymerase II promoter, GO:0048661 – positive regulation of smooth muscle cell proliferation, GO:0006954 – inflammatory response, and GO:0001666 – response to hypoxia (Figure 3b). In addition, 43 KEGG pathways were significantly enriched for these genes, including hsa05200: pathways related to cancer, hsa04668: TNF signaling pathway, hsa04010: MAPK signaling pathway, hsa04066: HIF-1 signaling pathway, and hsa04068: FoxO signaling pathway (Figure 3c).

3.3 Construction of PPI network

The SAH-related DEGs were entered into the STRING database, and a total of 830 PPI networks were generated. The PPI network, including 118 gene nodes, was constructed as shown in Figure 4a. The first ten hub genes, TNF, AKT1, TP53, MMP9, TLR4, STAT3, IL1B, TLR2, MYC, and CXCR4, were screened with the highest degree.

3.4 Construction of the drug–gene network

From CMAP database, a total of 23 chemicals were obtained to target SAH-related DEGs with the threshold of |Pearson R| > 0.75 and P < 0.05. The drug–gene pairs related to these 23 chemicals were further selected from the CTD database, and a total of 22 drug–gene pairs were obtained to establish a drug–gene network (Figure A1, Table A1). The network contained ten upregulated genes, five downregulated genes, and five small molecule drugs (coralyne, alexidine, enilconazole, chrysirin, and arachidonitrifluoromethane). Chrysirin was found to target more genes, such as TNF, AKT1, and MMP9.

3.5 CeRNA network construction

Using the DIANA-LncBase v2 database, seven lncRNA–miRNA interactions involving three miRNAs and five lncRNAs with the negative correlation of their expression levels were obtained. Then, the target genes were predicted for 3 miRNAs in lncRNA–miRNA interactions, and then the target genes were filtered by SAH-related DEGs, and a total of 21 pairs of miRNA–mRNA connections were found. The ceRNA network was established via integration with lncRNA–miRNA and miRNA–mRNA interactions (Figure 4b). The ceRNA network comprised 29 nodes, including 5 lncRNAs, 3 miRNAs, and 21 mRNAs. Notably, upregulated JMJD1C may function as a ceRNA to suppress the inhibitory effects of hsa-miR-204 on HDAC4 and SIRT1, thus leading to their upregulated expression. Similarly, upregulated MEG3 may regulate the expression of TGFBR3 and GSK3β by binding to hsa-miR-128. In addition, LINC01144 – hsa-miR-128 – ADRB2/TGFBR3 regulatory axis was found. We further performed correlation analysis for lncRNA and their associated mRNAs in ceRNA network (Table A2), and weak positive correlations were found. There was a significant positive correlation between LINC01287 and STAT3 (r = 0.35; p < 0.01), indicating that LINC01287 – hsa-miR-204 – STAT3 was a potential important ceRNA regulatory axis.

3.6 Screening and verification of SAH-related RNAs

LASSO and RFE algorithms were used to screen characteristic RNAs signatures from all RNAs in the three networks. In the training set (GSE73378), a total of 90 RNAs and 52 RNAs were obtained using LASSO and RFE, respectively (Figure 5a and b). Furthermore, a total of 38 overlapping RNAs were obtained as optimal characteristic RNAs signature, including 2 lncRNAs (JMJD1C-AS1 and LINC0144), 1 miRNA (hsa-miR-510), and 35 genes (TLR4, MMP9, ADRB2, TGFBR3, among others) (Table 1). The expression levels of the optimal characteristic RNAs signature in SAH and normal samples are displayed in Figure 6a and b. Only the two lncRNAs, one miRNA, and top ten mRNAs (ranking by log FC) were displayed. In the GSE73378 dataset, all the 13 RNAs were significantly differentially expressed in the SAH sample compared to that of control samples (Figure 6a). While, in the GSE36791 dataset, the two lncRNAs (JMJD1C-AS1 and LINC0144), hsa-miR-510, and mRNAs (KLF4 and TRPM4)
showed no statistical difference on their expression levels between SAH and normal samples (Figure 6b).

To validate the diagnostic ability of the optimal characteristic RNAs signature, the SVM classifier were constructed in GSE73378 dataset, which showed well predictive value for SAH patients with an AUC of 0.990 (Figure 6c).

The predictive value of these optimal characteristic RNAs signature was further validated in an external independent dataset (GSE36791). The SVM classifier still showed better performance with an AUC of 0.845 (Figure 6d). The results showed that the RNAs had a robust and stable predictive ability for SAH.

Figure 4: Networks construction. (a) The PPI network. The change in the color of the node from green to red indicates the change in the degree of significant difference from significantly down to up; the size of the node indicates the degree of connectivity of the node in the network. (b) The ceRNA network. Square, triangle, and circle represent IncRNA, miRNA, and mRNA, respectively. The change in the color of the node from green to red indicated the change in log FC from low to high.
These genes were enriched in the inflammatory response, cellular response to mechanical stimulus, TNF signaling pathway, and cancer-related pathways. Increasing studies have revealed that IA is closely related to the inflammatory response, cellular response to mechanical stimulus, TNF signaling pathway, and cancer-related pathways. These pathways are associated with SAH, and the TNF signaling pathway has been found to play an important role in the pathogenesis of SAH [43]. In IAs, TNF-α was up-regulated in wall tissues and associated with the type and diameter of the aneurysm [44]. According to these studies, we speculated that the TNF signaling pathway was implicated in SAH development.

PPI network for SAH-related DEGs showed that TNF, MMP9, and TLR4 were hub genes. It has been reported that venous levels of TNF-α1 associated with poor outcomes at 6 months for SAH [45], and down-regulating TNF-α can inhibit the formation of IAs in vivo [44]. Thus, decreasing TNF expression may have the potential to inhibit SAH. MMP9 was found to be associated with TLR4 signaling activation, and downregulating MMP9 induced by LPS has a neuroprotective effect on brain injury caused by SAH [46]. In addition, TLR4 is a key player in the regulation of inflammation, and it has been found to be correlated with poor prognosis in SAH [47]. Our present results also confirmed that TLR4 was up-expressed in SAH. Subsequently, by constructing a ceRNA network, it was suggested that the downregulated lncRNA MEG3 may be particularly important for SAH, as it may function as a ceRNA for upregulating hsa-miR-128 expression, thus leading to the downregulation of ADRB2 and TGFBR3. Previous studies have shown that MEG3 is highly expressed in SAH, and MEG3 may promote SAH-induced neuronal cell injury by inhibiting the PI3K/AKT signaling pathway [48]. However, MEG3 has also been found to promote platelet phagocytosis by decreasing miR-128 expression to protect VECs from senescence [49]. To the best of our knowledge, the regulatory mechanisms of MEG3 in SAH need further experimental confirmation. Furthermore, TGFBR3 is involved in the activation of the TGF-β signaling pathway, and TGFBR3 is downregulated in pancreatic ductal adenocarcinoma cells [50]. In present data, TGFBR3 was downregulated in SAH, and overexpression of TGFBR3 may be an important therapeutic target in SAH treatment.

We identified 38 optimal characteristic lncRNAs signatures from the lncRNAs in these networks, which were used to construct the SVM classifier. The results of ROC curves investigated that these lncRNAs (such as JMJDIC-ASI, LINCO1144, hsa-miR-510, TLR4, ADRB2, TGFBR3, and so on) were potential biomarkers for predicting SAH. MiR-510 has been reported to be significantly downregulated in ovarian serous carcinoma (OSC), and it is a novel candidate biomarker for predicting the symptoms of OSC [51]. However, the role of miR-510 and lncRNAs, JMJDIC-ASI and LINCO1144, in SAH has not been

4 Discussion

This study aimed to discover effective diagnosis biomarkers for SAH by the analysis of sequencing data, which have the potential to guide future clinical and basic medical studies. In the present research, we first identified 621 DEGs, of which 124 SAH-related DEGs were obtained using DisGeNET and GSEA. These genes were enriched in the inflammatory response, TNF signaling pathway, and cancer-related pathways. Increasing studies have revealed that IA is closely related to the inflammatory response [40,41]. Moreover, inflammation and immune response have been found to potentially contribute to the formation of IA [42]. Among these pathways associated with SAH, some studies have also confirmed the role of the TNF signaling pathway in diseases including SAH. The potential of TNF-α inhibitors has been reported to impact the pathogenesis of aneurismal SAH, and the TNF-α signaling pathway has been found to play an important role in the pathogenesis of SAH [43]. In IAs, TNF-α was up-expressed in wall tissues and associated with the type and diameter of the aneurysm [44]. According to these studies, we speculated that the TNF signaling pathway was implicated in SAH development.

PPI network for SAH-related DEGs showed that TNF, MMP9, and TLR4 were hub genes. It has been reported that venous levels of TNF-R1 were associated with poor outcomes at 6 months for SAH [45], and down-regulating TNF-α can inhibit the formation of IAs in vivo [44]. Thus, decreasing TNF expression may have the potential to inhibi
Table 1: The optimal 38 RNAs signature (including 2 lncRNAs, 1 mRNA, and 35 genes) screened by LASSO and RFE algorithms

| ID        | Symbol     | Type          | Log₂ FC       | P value     | FDR          | Regulation (up/down) |
|-----------|------------|---------------|---------------|-------------|--------------|----------------------|
| ILMN_1677589 | JMJD1C-AS1 | lncRNA       | 0.297887125  | 5.10 × 10^6 | 0.004137356 | Up                   |
| ILMN_1690382 | LINCO1144  | lncRNA       | −0.269639525  | 2.14 × 10^6 | 0.00173673 | Down                 |
| ILMN_3310690 | hsa-miR-510 | mRNA        | −0.28978015  | 5.83 × 10^6 | 0.00472543 | Down                 |
| ILMN_1662809 | SETD2      | mRNA        | −0.27352525  | 0.000143801 | 0.00931808 | Down                 |
| ILMN_1666924 | PINK1      | mRNA        | 0.349209875 | 0.000468661 | 0.03036922 | Up                   |
| ILMN_1671054 | HLA-A      | mRNA        | 0.27793335  | 0.00057726  | 0.03746671 | Up                   |
| ILMN_1671818 | UTS2       | mRNA        | −0.304786475 | 0.000176825 | 0.01145823 | Down                 |
| ILMN_1677511 | PTG52      | mRNA        | 0.2805209  | 0.000522788 | 0.03387664 | Up                   |
| ILMN_1677532 | TARDBP     | mRNA        | −0.3606863  | 9.19 × 10^5 | 0.00959515 | Down                 |
| ILMN_1679401 | TRPM4      | mRNA        | 0.350872575 | 1.62 × 10^5 | 0.00105106 | Up                   |
| ILMN_1680424 | CTSG       | mRNA        | −0.425172725 | 0.000364996 | 0.02365172 | Down                 |
| ILMN_1680453 | ITM2C      | mRNA        | −0.50531015 | 4.88 × 10^5 | 0.03951964 | Down                 |
| ILMN_1680618 | MYC        | mRNA        | 0.2905886  | 0.000607897 | 0.03931971 | Up                   |
| ILMN_1689734 | IL1RN      | mRNA        | 0.341397425 | 0.000695521 | 0.04506973 | Up                   |
| ILMN_1695590 | ADRB2      | mRNA        | −0.3777768  | 0.000218822 | 0.01679666 | Down                 |
| ILMN_1703617 | AHS1A      | mRNA        | −0.271606475 | 0.000419963 | 0.02721361 | Down                 |
| ILMN_1706217 | TLR4       | mRNA        | 0.464493425 | 9.57 × 10^5 | 0.00619866 | Up                   |
| ILMN_1708934 | ADM        | mRNA        | 0.772645425 | 1.71 × 10^5 | 0.01386624 | Up                   |
| ILMN_1710410 | CHRM3      | mRNA        | −0.27857305 | 7.68 × 10^5 | 0.00497428 | Down                 |
| ILMN_1715715 | CEBPA      | mRNA        | −0.30413125 | 0.000418064 | 0.02790539 | Down                 |
| ILMN_1722622 | CD163      | mRNA        | 0.27239935 | 0.000605937 | 0.03926473 | Up                   |
| ILMN_1728197 | CLDN5      | mRNA        | 0.32183615 | 0.000479949 | 0.03110075 | Up                   |
| ILMN_1729161 | NOTCH1     | mRNA        | 0.30529195 | 5.49 × 10^5 | 0.04447982 | Up                   |
| ILMN_1734830 | MTHFR      | mRNA        | −0.28369415 | 3.74 × 10^5 | 0.03025829 | Down                 |
| ILMN_1748661 | AKT1       | mRNA        | 0.276209675 | 0.000242712 | 0.01572771 | Up                   |
| ILMN_1760778 | ENG        | mRNA        | −0.2935118 | 0.000170384 | 0.01040088 | Down                 |
| ILMN_1779857 | KLF4       | mRNA        | 0.374529375 | 0.000160395 | 0.01039626 | Up                   |
| ILMN_1783889 | PRKAA1     | mRNA        | 0.2661473  | 1.77 × 10^5 | 0.01436973 | Up                   |
| ILMN_1784287 | TGFBR3     | mRNA        | −0.509308675 | 0.0001915  | 0.01240917 | Down                 |
| ILMN_1787386 | ADAMTS13    | mRNA        | 0.2707362 | 4.82 × 10^5 | 0.00312572 | Up                   |
| ILMN_1791847 | DAPK2      | mRNA        | −0.297182 | 0.000465953 | 0.03019377 | Down                 |
| ILMN_1796180 | CRY2       | mRNA        | −0.294307375 | 4.04 × 10^6 | 0.00326864 | Down                 |
| ILMN_1796316 | MMP9       | mRNA        | −0.6874905 | 0.000225147 | 0.01458955 | Down                 |
| ILMN_1800425 | SLC9A1     | mRNA        | −0.319644675 | 0.000369868 | 0.02396744 | Down                 |
| ILMN_1809613 | NGEF       | mRNA        | −0.283432825 | 9.99 × 10^5 | 0.00647363 | Down                 |
| ILMN_1814327 | AGTR1      | mRNA        | −0.29794675 | 9.43 × 10^5 | 0.00611218 | Down                 |
| ILMN_1815057 | PDGFRB     | mRNA        | −0.338885 | 3.48 × 10^5 | 0.00225695 | Down                 |
| ILMN_2267914 | CD68       | mRNA        | −0.305515875 | 0.000622021 | 0.04030697 | Down                 |

reported. *LINCO1144-hsa-miR-128-ADRB2/TGFBR3* regulatory axis was found from our ceRNA network, *LINCO1144* may play a role in SAH by regulating *ADRB2* and *TGFBR3* expression. *ADRB2* encodes adrenoreceptor beta 2. Adrenoreceptor polymorphisms are associated with an increased risk of cardiac abnormalities after SAH [52]. β-adrenoreceptor antagonists have been found to suppress the elevation of IL-6 after SAH in rats [53]. *TGFBR3* is a transforming growth factor (TGF) beta receptor. TGF-β1/Smad/CTGF pathway was inhibited by rhDecorin to prevent development of hydrocephalus after SAH [54]. Knockdown of TGF-β1 in human umbilical cord-derived mesenchymal stem cells could attenuate SAH-induced chronic hydrocephalus, upregulation of inflammatory cytokines, and other behavioral changes [55]. Considering the important role of *ADRB2* and *TGFBR3* in SAH, we speculated that *LINCO1144* was involved in the development of SAH. However, elucidation of the roles of these lncRNAs associated with the screening and prevention of patients with SAH requires further investigation.

We suggested that these identified RNA biomarkers could help doctors to predict the risk of SAH and intervene as soon as possible. Although the feature RNAs were identified just based on the GSE73378 dataset, these feature RNAs still showed well predictive performance in another dataset with different inclusion criteria for patients (patients had the last episode of aneurysmal SAH at least
two years in GSE73378 dataset, while this is not mentioned in GSE36791 dataset), which further indicated the stability and reliability of feature RNAs in predicting risk of SAH. Additionally, though the expression and predictive value of these feature RNAs have been validated using another external independent dataset (GSE36791), experimental verification is still indispensable in the future. In addition, the clinical value of these biomarkers should be further confirmed.

5 Conclusion

In summary, gene expression profile analysis revealed a large scale of expression pattern changes in RNAs under the pathophysiology of SAH, and they were mainly implicated in the inflammatory response, TNF signaling pathway. We further identified 38 RNAs, including 2 lncRNAs (JMJD1C-AS1 and LINC01144), 1 miRNA (hsa-miR-510), and 35 genes (TLR4, ADRB2, TGFBR3, among others) as potential blood biomarkers for screening patients with SAH. This 38 RNAs signature had a better predictive performance for SAH risk. LINC01144 might regulate ADRB2/TGFBR3 expression by sponging hsa-miR-128. These findings of the present study contributed to understanding the molecular mechanism of SAH deeply and also provided the potential biomarkers for the screening and prevention of SAH. However, their application values should be further validated in clinical.

Funding information: The authors state no funding involved.

Conflict of interest: The authors state no conflict of interest.
Data availability statement: The datasets generated during and/or analyzed during the current study are available from the corresponding author on reasonable request.

References

[1] Carpenter CR, Hussain AM, Ward MJ, Zipfel GJ, Fowler S, Pines JM, et al. Spontaneous subarachnoid hemorrhage: a systematic review and meta-analysis describing the diagnostic accuracy of history, physical examination, imaging, and lumbar puncture with an exploration of test thresholds. Academic Emerg Med Off J Soc Academic Emerg Med. 2016;23(9):963–1003.

[2] Bederson JB, Connolly Jr. ES, Batjer HH, Dacey RG, Dion JE, Diringer MN, et al. Guidelines for the management of aneurysmal subarachnoid hemorrhage: a statement for healthcare professionals from a special writing group of the Stroke council, American Heart Association. Stroke. 2009;40(3):994–1025.

[3] Wang Q, Luo Q, Yang Z, Zhao YH, Li J, Wang J, et al. Weighted gene co-expression network analysis identified six hub genes associated with rupture of intracranial aneurysms. PLoS One. 2020;15(2):e0229308.

[4] Nieuwkamp DJ, Setz LE, Algra A, Linn FH, de Rooij NK, Rinkel GJ. Changes in case fatality of aneurysmal subarachnoid haemorrhage over time, according to age, sex, and region: a meta-analysis. Lancet Neurol. 2009;8(7):635–42.

[5] Korja M, Silventoinen K, McCarron P, Zdravkovic S, Skytte A, Haapanen A, et al. Genetic epidemiology of spontaneous subarachnoid hemorrhage: Nordic twin study. Stroke. 2010;41(11):2458–62.

[6] Skodvin T, Evju Ø, Sorteborg A, Isaksen JG. Prerupture intracranial aneurysm morphology in predicting risk of rupture: a matched case-control study. Neurosurgery. 2019;84(1):132–40.

[7] Rivero-Arias O, Gray A, Wolstenholme J. Burden of disease and costs of aneurysmal subarachnoid haemorrhage (aSAH) in the United Kingdom. Cost Effectiveness Resour Allocat C/E. 2010;8(1):1–2.

[8] Wang J, Wang Y, Kong F, Han R, Song W, Chen D, et al. Identification of a six-gene prognostic signature for oral squamous cell carcinoma. J Cell Physiol. 2020;235(3):3056–68.

[9] Zhang X, Wang W, Zhu W, Dong J, Cheng Y, Yin Z, et al. Mechanisms and functions of long non-coding RNAs at multiple regulatory levels. Int J Mol Sci. 2019;20(22):5573.

[10] Huang F, Yi J, Zhou T, Gong X, Jiang H, Yao X. Toward understanding non-coding RNA roles in intracranial aneurysms and subarachnoid hemorrhage. Transl Neurosci. 2017;8:54–64.

[11] Gareev I, Beyeleri O, Allew G, Pavlov V, Izmailov A, Zhang Y, et al. The role of long non-coding RNAs in intracranial aneurysms and subarachnoid hemorrhage. Life (Basel, Switzerland). 2020;10(9):155.

[12] Ouyang Y, Jiang Y, Yu M, Zhang M, Tan Z. Upregulation of MALAT1 expression predicts a poor prognosis in the development of intracranial aneurysm (IA). Int J Clin Exp Pathol. 2017;10(5):5907–12.

[13] Li P, Zhang Q, Wu X, Yang X, Zhang Y, Li Y, et al. Circulating microRNAs serve as novel biological markers for intracranial aneurysms. J Am Heart Assoc. 2014;3(5):e000972.

[14] Przybysc-Szymanska MM, Ashley Jr. WW. Biomarker discovery in cerebral vasospasm after aneurysmal subarachnoid hemorrhage. J Stroke Cerebrovasc Diseases Off J Natl Stroke Assoc. 2015;24(7):1453–64.

[15] van’t Hof FN, Ruigrok YM, Medic J, Sanjabi B, van der Vlies P, Rinkel GJ, et al. Whole blood gene expression profiles of patients with a past aneurysmal subarachnoid hemorrhage. PLoS One. 2015;10(10):e0139352.

[16] Pera J, Korostynski M, Golda S, Piechota M, Dzbek J, Krzysztkowski T, et al. Gene expression profiling of blood in ruptured intracranial aneurysms: in search of biomarkers. J Cereb Blood Flow Metab Off J Int Soc Cereb Blood Flow Metabolism. 2013;33(7):1025–31.

[17] Ritchie ME, Phipson B, Wu D, Hu Y, Law CW, Shi W, et al. limma powers differential expression analyses for RNA-sequencing and microarray studies. Nucleic Acids Res. 2015;43(7):e47.

[18] Szekely GJ, Rizzo ML. Hierarchical clustering via joint between-within distances: extending ward’s minimum variance method. J Classification. 2005;22(2):151–83.

[19] Oh SJ, Joung JG, Chang JH, Zhang BT. Construction of phylogenetic trees by kernel-based comparative analysis of metabolic networks. BMC Bioinform. 2006;7:284.

[20] Wang L, Cao C, Ma Q, Zeng Q, Wang H, Cheng Z, et al. RNA-seq analyses of multiple meristems of soybean: novel and alternative transcripts, evolutionary and functional implications. BMC Plant Biol. 2014;14:169.

[21] Piñero J, Bravo Á, Queralt-Rosina N, Gutiérrez-Sacristán A, Deu-Pons J, Centeno E, et al. DisGeNET: a comprehensive platform integrating information on human disease-associated genes and variants. Nucleic Acids Res. 2017;45(D1):D833–9.

[22] Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA, et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci U S Am. 2005;102(43):15545–50.

[23] Huang da W, Sherman BT, Lempicki RA. Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat Protoc. 2009;4(1):46–57.

[24] Huang da W, Sherman BT, Lempicki RA. Bioinformatics enrichment tools: paths toward the comprehensive functional analysis of large gene lists. Nucleic Acids Res. 2009;37(1):1–13.

[25] Szklarczyk D, Morris JR, Cook H, Kuhn M, Wyder S, SantosZF, et al. The STRING database in 2017: quality-controlled protein–protein association networks, made broadly accessible. Nucleic Acids Res. 2017;45(1):D362–d8.

[26] Shannon P, Markiel A, Ozier O, Baliga NS, Wang JT, Ramage D, et al. Cytoscape: a software environment for integrated models of biomolecular interaction networks. Genome Res. 2003;13(11):2498–504.

[27] Lamb J, Crawford ED, Peck D, Modell JW, Blat IC, Wrobel MJ, et al. The connectivity map: using gene-expression signatures to connect small molecules, genes, and disease. Sci (N York, NY). 2006;313(5795):1929–35.
[28] Lamb J. The connectivity map: a new tool for biomedical research. Nat Rev Cancer. 2007;7(1):54–60.
[29] Davis AP, Wiegers TC, Grondin CJ, Johnson RJ, Scialy D, Wiegers J, et al. Leveraging the comparative toxicogenomics database to fill in knowledge gaps for environmental health: a test case for air pollution-induced cardiovascular disease. Toxicol Sci Off J Soc Toxicol. 2020;177(2):392–404.
[30] Paraskevopoulou MD, Viachos IS, Karagkouni D, Georgakilas G, Kanellos I, Vergoulis T, et al. DIANA-LncBase v2: indexing microRNA targets on non-coding transcripts. Nucleic Acids Res. 2016;44(D1):D231–8.
[31] Agarwal V, Bell GW, Nam JW, Bartel DP. Predicting effective microRNA target sites in mammalian mRNAs. eLife. 2015;4:e05005.
[32] Lu T, Chen S, Qu L, Wang Y, Chen HD, He C. Identification of a five-miRNA signature predicting survival in cutaneous melanoma cancer patients. PeerJ. 2019;7:e7831.
[33] Deng Z, Wang Y, Fang X, Yan F, Pan H, Gu L, et al. Research on miRNA-195 and target gene CDK6 in oral verrucous carcinoma. Cancer Gene Ther. 2017;24(7):282–8.
[34] Loher P, Rigoutsos I. Interactive exploration of RNA22 microRNA target predictions. Bioinforma (Oxford, Engl). 2012;28(24):3322–3.
[35] Chen B, Liu B. miRNA-381 inhibits the invasion of renal carcinoma and the underlying mechanisms. J Cent South Univ Med Sci. 2015;40(10):1053–9.
[36] Efron B, Hastie T, Johnstone I, Tibshirani R. Least angle regression (with discussions). Ann Stat. 2004;32(2):409–99.
[37] Kuhn. M. Building predictive models in R using the caret package. J Stat Softw. 2008;28(1):1–26.
[38] Meyer D. Support vector machines: the interface to libsvm in package e1071. R N. 2013;1:1–3.
[39] Robin X, Turck N, Hainard A, Tiberti N, Lisacek F, Sanchez JC, et al. pROC: an open-source package for R and S + to analyze and compare ROC curves. BMC Bioinforma. 2011;12:77.
[40] Kleinloog R, Verweij BH, van der Vlies P, Deelen P, Swertz MA, de Muynck L, et al. RNA sequencing analysis of intracranial aneurysms. Stroke. 2016;47(5):1286–93.
[41] Pera J, Korostynski M, Krzyzowski T, Czopek J, Słowiak A, Dziedzic T, et al. Gene expression profiles in human ruptured and unruptured intracranial aneurysms: what is the role of inflammation? Stroke. 2010;41(2):224–31.
[42] Xu Z, Li H, Song J, Han B, Wang Z, Cao Y, et al. Meta-analysis of microarray-based expression profiles to identify differentially expressed genes in intracranial aneurysms. World Neurosurg. 2017;97:661–8.
[43] Young AM, Karri SK, You W, Ogilvy CS. Specific TNF-alpha inhibition in cerebral aneurysm formation and subarachnoid hemorrhage. Curr Drug Saf. 2012;7(3):190–6.
[44] Fan W, Liu Y, Li C, Qu X, Zheng G, Zhang Q, et al. microRNA-331-3p maintains the contractile type of vascular smooth muscle cells by regulating TNF-alpha and CD14 in intracranial aneurysm. Neuropharmacology. 2020;164:107858.
[45] Fragata I, Bustamante A, Penalba A, Ferreira P, Nunes AP, Canhão P, et al. TNF-R1 correlates with cerebral perfusion and acute ischemia following subarachnoid hemorrhage. Neurocritical Care. 2020;33(3):679–87.
[46] Wang WW, Chen B, Lei CB, Liu GX, Wang YG, Yi C, et al. miR-582-5p inhibits invasion and migration of salivary adenoid cystic carcinoma cells by targeting FOXC1. Jpn J Clin Oncol. 2017;47(8):690–8.
[47] Ma C, Zhou W, Yan Z, Qu M, Bu X. Toll-like receptor 4 (TLR4) is correlated with delayed cerebral ischemia (DCI) and poor prognosis in aneurysmal subarachnoid hemorrhage. J Neurological Sci. 2015;359(1–2):67–71.
[48] Liang Z, Chi YI, Lin GQ, Xiao LF, Su GL, Yang LM. LncRNA MEG3 participates in neuronal cell injury induced by subarachnoid hemorrhage via inhibiting the PI3K/Akt pathway. Eur Rev Med Pharmacol Sci. 2018;22(9):2824–31.
[49] Lan Y, Li YJ, Li DJ, Li P, Wang JY, Diao YP, et al. Long non-coding RNA MEG3 prevents vascular endothelial cell senescence by impairing miR-128-dependent Gidin downregulation. Am J Physiol Cell Physiol. 2019;316(6):C830–43.
[50] Yin Z, Ma T, Huang B, Lin L, Zhou Y, Yan J, et al. Macrophage-derived exosomal microRNA-501-3p promotes protection of pancreatic ductal adenocarcinoma through the TGFBR3-mediated TGF-β signaling pathway. J Exp Clin Cancer Res CR. 2019;38(1):310.
[51] Yu X, Zhang X, Bi T, Ding Y, Zhao J, Wang C, et al. MiRNA expression signature for potentially predicting the prognosis of ovarian serous carcinoma. Tumour Biol J Int Soc Oncodev Biol Med. 2013;34(6):3501–8.
[52] Zaro GP, Canhão P, et al. TNF-alpha and its receptor TNFR1 correlates with cerebral perfusion and acute ischemia following subarachnoid hemorrhage. Stroke. 2006;37(5):1903–10.
[53] Kato H, Kawaguchi M, Inoue S, Hirai K, Furuya H. The effect of TNF-alpha on cerebral blood flow in the chronic phase of subarachnoid hemorrhage. Stroke. 2005;36(7):1704–9.
[54] Han X, Lei Y, Liu J, Zhang X, Zhong Y, Hou J, et al. Effect of TNF-alpha on the expression of TNF-alpha receptor 1 in subarachnoid hemorrhage. Neurogastroenterol Motil. 2016;28(5):e13268.
[55] Chen H, Chen L, Xie D, Niu J. Protective effects of transforming growth factor-β1 knockdown in human umbilical cord mesenchymal stem cells against subarachnoid hemorrhage in a rat model. Cerebrovascular Diseases (Basel, Switzerland). 2020;49(1):79–87.
Appendix

Figure A1: The drug-gene network. Circles and diamonds represent genes and chemicals, respectively. Red color represented the upregulated gene, and green represented a downregulated gene.
### Table A1: The detailed information for the predicted drug–gene interactions

| # Chemical name | Gene symbol | Chemical ID | Gene ID | Organism | Organism ID | Interaction | Interaction actions | PubMed IDs |
|-----------------|-------------|-------------|---------|----------|-------------|-------------|---------------------|------------|
| **Coralyne**    | IL6R        | C000666     | 3570    | Homo sapiens | 9606 | Coralyne results in decreased expression of IL6R protein modified form | Decreases expression | 20116850 |
| **Alexidine**   | IL6R        | C001570     | 3570    | Homo sapiens | 9606 | Alexidine results in decreased expression of IL6R protein modified form | Decreases expression | 20116850 |
| **Enilconazole**| ALDH2       | C017435     | 217     | Homo sapiens | 9606 | Enilconazole results in decreased expression of ALDH2 mRNA | Decreases expression | 32201337 |
| **Enilconazole**| IL1B        | C017435     | 3553    | Mus musculus | 10090 | Enilconazole results in increased expression of IL1B mRNA | Increases expression | 27393971 |
| **Enilconazole**| KLF4        | C017435     | 9314    | Mus musculus | 10090 | Enilconazole affects the expression of KLF4 mRNA | Affects expression | 29106682 |
| **Enilconazole**| LCN2        | C017435     | 3934    | Mus musculus | 10090 | Enilconazole results in increased expression of LCN2 | Increases expression | 27393971 |
| **Enilconazole**| PTGS2       | C017435     | 5743    | Mus musculus | 10090 | Enilconazole binds to and results in decreased activity of PTGS2 protein which results in decreased chemical synthesis of Prostaglandin D2 | Affects binding|decreases activity|decreases chemical synthesis|decreases secretion | 26359731 |
| **Enilconazole**| TNF         | C017435     | 7124    | Mus musculus | 10090 | Enilconazole results in increased expression of TNF mRNA | Increases expression | 27393971 |
| **Chrysin**     | AKT1        | C043561     | 207     | Homo sapiens | 9606 | Chrysin inhibits the reaction [AKT1 protein results in increased expression of MMP10 protein] | Decreases expression|increases expression | 24122885 |
| **Chrysin**     | GCLC        | C043561     | 2729    | Rattus norvegicus | 10116 | Chrysin dose-dependently up-regulated the protein expression of glutamate cysteine ligase (GCL) catalytic (GCLC) and modifier subunit (GCLM) | Affects binding|decreases activity|decreases reaction|increases chemical synthesis | 22864849 |
| **Chrysin**     | IL1B        | C043561     | 3553    | Homo sapiens | 9606 | Chrysin inhibits the reaction [nickel chloride results in increased expression of IL1B protein] | Decreases reaction|increases expression | 30016632 |
| **Chrysin**     | MMP10       | C043561     | 4319    | Homo sapiens | 9606 | Chrysin inhibits the reaction [AKT1 protein results in increased expression of MMP10 protein] | Decreases reaction|increases expression | 24122885 |
| **Chrysin**     | MMP9        | C043561     | 4318    | Homo sapiens | 9606 | Chrysin inhibits the reaction [nickel chloride results in increased expression of and results in increased activity of MMP9 protein] | Decreases reaction|increases expression | 30016632 |
| **Chrysin**     | MYD88       | C043561     | 4615    | Homo sapiens | 9606 | Chrysin inhibits the reaction [nickel chloride results in increased expression of MYD88 mRNA] | Decreases reaction|increases expression | 30016632 |

(Continued)
| # Chemical name | Gene symbol | Chemical ID | Gene ID | Organism | Organism ID | Interaction | Interaction actions | PubMed IDs |
|-----------------|-------------|-------------|---------|----------|-------------|-------------|---------------------|-----------|
| Chrysin         | PTGS2       | C043561     | 5743    | Rattus   | 10116       | Chrysin inhibits the reaction [Freund's Adjuvant results in increased expression of PTGS2 protein] | Decreases reaction | 24932515 |
| Chrysin         | RELA        | C043561     | 5970    | Homo sapiens | 9606       | Chrysin results in decreased expression of RELA protein | Decreases expression | 30578657 |
| Chrysin         | TLR4        | C043561     | 7099    | Rattus norvegicus | 10116 | Chrysin inhibits the reaction [Thioacetamide results in increased expression of TLR4 mRNA] | Decreases reaction | 30500344 |
| Chrysin         | TNF         | C043561     | 7124    | Rattus norvegicus | 10116 | Silymarin promotes the reaction (chrysin inhibits the reaction [Acetaminophen results in increased expression of TNF protein]) | Decreases reaction | 31625388 |
| Chrysin         | TP53        | C043561     | 7157    | Rattus norvegicus | 10116 | Chrysin inhibits the reaction [Testosterone results in decreased expression of TP53 mRNA] | Decreases expression | 29247772 |
| Arachidonyl trifluoromethane | IL1B | C081565     | 3553    | Homo sapiens | 9606 | Arachidonyl trifluoromethane inhibits the reaction (NAD inhibits the reaction [3′-O-(4-benzoyl)benzoyladenosine 5′-triphosphate results in increased secretion of IL1B protein]) | Decreases reaction | 29642561 |
| Arachidonyl trifluoromethane | PTGS2 | C081565     | 5743    | Mus musculus | 10090 | Arachidonyl trifluoromethane inhibits the reaction [tetrachlorodibenzodioxin results in increased activity of PTGS2 protein] | Decreases reaction | 19063610 |
| Arachidonyl trifluoromethane | TNF | C081565     | 7124    | Homo sapiens | 9606 | Arachidonyl trifluoromethane inhibits the reaction [TNF protein results in increased expression of SOD2] | Decreases reaction | 11264281 |
Table A2: Correlation analysis results for lncRNA and their associated mRNAs in ceRNA network

| DElncRNA | DEmRNA | P_value | Cor        |
|----------|--------|---------|------------|
| LINC01287 | STAT3 | 0.002185022 | 0.346095443 |
| LINC01144 | RABGEF1 | 0.01566732 | 0.076406814 |
| MEG3 | ENO2 | 0.035022817 | 0.0051276 |
| LINC00305 | DENR | 0.07519792 | 0.171671665 |
| LINC01144 | GORASP1 | 0.03475631 | 0.012136242 |
| MEG3 | GSK3B | 0.115897555 | 0.22090058 |
| JMJD1C-AS1 | HDAC4 | 0.132741279 | 0.146195814 |
| LINC01287 | CXCR4 | 0.147614043 | 0.146372974 |
| LINC01144 | SETD2 | 0.154924645 | 0.031606782 |
| LINC00305 | CD44 | 0.16762594 | 0.030033851 |
| MEG3 | MNT | 0.194071109 | 0.17576912 |
| LINC00305 | RPS6KA5 | 0.29245268 | 0.015048382 |
| LINC00305 | TXNIP | 0.412733498 | 0.015264142 |
| MEG3 | GORASP1 | 0.414050273 | 0.214254126 |
| JMJD1C-AS1 | CXCR4 | 0.42598672 | 0.19223608 |
| MEG3 | ADRB2 | 0.439984979 | 0.254273266 |
| JMJD1C-AS1 | BIRC2 | 0.472841434 | 0.170991838 |
| LINC00305 | SIRT1 | 0.538544746 | 0.00323312 |
| JMJD1C-AS1 | STAT3 | 0.55495082 | 0.086126879 |
| JMJD1C-AS1 | HIF1A | 0.695596063 | 0.03574985 |
| MEG3 | RABGEF1 | 0.708916655 | 0.175062031 |
| LINC00305 | CXCR4 | 0.746472986 | 0.199083358 |
| LINC00305 | TGFBR2 | 0.759578309 | 0.038602594 |
| LINC00305 | BIRC2 | 0.8264802 | 0.066127226 |
| MEG3 | TGFBR3 | 0.862145773 | 0.160751671 |